Dror Bin, Chief Executive Officer, Israel Innovation Authority

Bankers
Michael Margolis, Senior Managing Director, Head of Healthcare Investment Banking, Oppenheimer & Co.
Michael Rice, Founding Partner, LifeSci Advisors

Venture Capital
Nick Pachuda, MD, General Partner, Neovate Capital Partners
Mitchell Gold, MD, Venture Partner, Frazier Life Scienses
Ittai Harel, Managing Partner, Pitango Venture Capital
Dr. Jing Bao, MD, PhD, Partner, Shanghai Healthcare Capital (SHC)
Dr. Craig Yeshion, MD, Managing Director, Specialty Pharmaceuticals & Medical Devices, Perceptive Advisors

Dr. Boaz Hirshberg, MD, Senior Vice President, Clinical Development Unit Head, Internal Medicine, Regeneron | Regeneron: Relentless Innovation Powering an Impactful Pipeline from Allergy to Obesity and Beyond

HALL A

(I&I) Immunology and Inflammation Reclaim top Priorities in BioPharma: Driver and Opportunities?

Moderators:
Iris Grossman, PhD, Chief Therapeutics Officer, Eleven Therapeutics
Prof. Amnon Peled, PhD, Hadassah Medical Center

Keynote Speakers

Prof. Dror Mevorach, MD, Chairman of Medicine &Director of the Rheumatology Research Centre, Hadassah-Hebrew University Hospital & School of Medicine, Jerusalem, A game changer in autoimmunity: CAR T and bispecific antibodies
Dr. Yael Marantz, PhD, Vice President, VP Nonclinical Development Teva Pharmaceuticals
Mayan Katz, Partner, Tech & Life Sciences Group, Goodwin Procter LLP

Company Presenters
Prof. Dror Harats, MD, CEO & Co-Founder, ImmuneWalk, New Target for Treatment of Immune Inflammatory Diseases – From Novel Biology to First-in-Human
Adi Mor, PhD, Co-Founder, CEO, CSO, Chemomab Therapeutics, Nebokitug- A first in class drug with disease modifying potential for inflammatory and fibrotic diseases
Prof. Amnon Peled, PhD, Co-Founder, Associate Professor and the Director of the Gene Therapy Institute, Alon Bio, BKT300, a novel anti-inflammatory small molecule that targets PRC1 for the treatment of atopic dermatitis
Prof. Rifaat Safadi, MD, Professor, The Hebrew University HEPACURE PHARMA, Immunotherapy against a novel neuroligin-4X /β-neurexin checkpoint reverses natural killer cell exhaustion and halts liver fibrogenesis 
Kfir Schreiber, Co-Founder & CEO, DeepCure, DeepCure
Jonathan Solomon, CEO, BiomX, Precision Phage Therapy for Chronic Diabetic Foot Infections
Dr. Tali Stauber, MD, Co-Founder, Zelig Therapeuticsת Curing Allergy by Specifically Eliminating Human IgE-Producing B cells

HALL B

Frontiers in Biochip and Bio-Devices: Advancing Technological Systems with Cutting-Edge Biology

Personalized Pathways: Genetic and Cellular Based Advances for Rare and Complex Diseases

1. Keynote Speaker Prof.  Gidi Rechavi– 
Tailoring ASOs for the treatment of rare diseases

2. Personal story – Noam Baumatz
From Loss to Lifesaving Science: A Personal Journey

3. Dr. Gili Hart – The present and future of Cell and Gene therapies

Part 2 – Gene and Cell therapies short talks 
A. SpliSense – Lital Friedman; VP Clinical & Regulatory Affairs
Title: Transformative RNA Based Treatments for Orphan and Large Unmet Pulmonary
Diseases

B. Lempo Therapeutics – Dr. Oren Glanz; CEO
Title: – Pioneering CRISPR Gene Editing to Calibrate the Immune System and Eliminate
Collateral Damages

C. Enlivex – Dr. Oren Hershkovitz; CEO
Enlivex, Title: – Harnessing the natural healing power of macrophages to treat inflammatory
diseases

D. Minovia, Dr. Natalie Yivgi Ohana, CEO, Title: Mitochondrial Augmentation Technology: updates on Pearson Syndrome and MDS
clinical programs

E. CYTORA- Dr. Yona Geffen; CEO
Title: Harnessing the Unique Healing Potential of Human Oral Mucosa Stem Cells for
Treating Complex Multifactorial Diseases

F. Sheba ( CAR-T )- Jonathan Esensten, Sheba Medical Center
Title: Accelerating cell and gene therapies into the clinic with in-house manufacturing at

Part 3- Panel discussion 
Ayal Hendel– The Israeli eco-system in the era of personalized pathways 

HALL A

Illuminating the Path: Innovations and Challenges in Eye Care

Moderators:
Prof. Anat Loewenstein, MD, President of the Israeli Ophthalmological Society, Dean of the Faculty of Medicine, Tel Aviv University, Chairperson of Ophthalmology, Sourasky Medical Center
Dr. Barak Azmon, MD, Director, Press-By
Jonathan Weyne, MD, Vice President Ophthalmology Therapeutic, Regeneron
Prof. Itay Chowers, Professor of Ophthalmology, & Chairman at the Division of Ophthalmology of the Hadassah – Hebrew University Medical Center

Keynote
Jonathan Weyne, MD, Vice President Ophthalmology Therapeutic, Regeneron  

Company Presenters
Aryeh Batt, CEO & Co-Founder, Precise Bio
Elad Kedar, CEO, Orasis Pharmaceuticals, Orasis Pharmaceuticals
Marianna Truman, Co-Founder & CEO, Orsight Pharma, AD-3281: a first-in-class METAP2 inhibitor targeting insufficient response in neovascular AMD
Dana Rabinovich, PhD, Co-Founder & CEO, OphtiMed RX, Saving Sight from Dry AMD Using Anti-Senescence Therapy
Prof. (Emeritus) Michael Belkin, MD, Advisor, Former Head of the Ophthalmology Dpt., PBM Medical Technologies, Retinal diseases by photobiomodulation
Nikolai Kunicher, PhD, CEO, Neuro Trigger, NeuroTrigger
Daria Lemann Blumenthal, CEO, Nano Drops, Nano Drops, Peace of Mind with NanoDrops Adjustable Vision Correction
Asaf Shiloni, Co-Founder & CEO, XOLTAR, XOLTAR: Scaling Humanlike Patient Support Through AI Companions
Almog Aley-Raz, Co-Founder, CEO & VP R&D, CorNeat Vision, Transforming Lives: The CorNeat KPro artificial cornea clinical study progress
Moshe Weinstein, CEO, Everads Therapy, Optimizing Treatment of Retinal Disease via Suprachoroidal Delivery

HALL B

AI’s Next Leap in HealthTech – From Buzzwords (Gen AI, Agentic, LLM and Foundation Models) to Real World examples

Moderator and Opening Remarks
Avi Veidman, CEO, Nucleai

Company Presenters
Amit Bleiweiss, Senior Data Scientist, NVIDIA, Medicine Reimagined: Harnessing the Power of Digital and Physical AI

Daniel Rabina, Healthcare & Life Sciences Startups Business Development Manager, AWS

Shelly Yehezkely, VP of AI, VIZ, Transforming Care Coordination with GenAI

Eliron Amir, CEO, Serial AI/Health Entrepreneur, Rounds Health

Samuel Jefroykin, Director of Data & Research, Eleos Health

Dr. Robert Klempfner, MD, Co-Founder & Chief Medical Officer, AISAP Ltd, The use of LLMs for rapid model development in point of care imaging

Dana Sinai, PhD, Clinical Psychologist, VP Conversational AI, Laguna Health, GenAI That Care Teams Trust: How Laguna pushes the envelope of GenAI impact and trust in healthcare

HALL C

The Next Bite; Evidence-Based Bio-Food by Design

Moderator: 
Tammy Meiron, PhD, Chief Technology Officer, Fresh Start FoodTech Incubator

Keynote Speakers
Prof. Uri Lesmes, Associate Professor, Technion – Israel Institute of Technology | Smart Reformulation of Food for Health of Different

Populations
Prof. Assaf Zinger, Assistant Professor, Technion – Israel Institute of Technology |Learning from Nature How to Target Diseases

Company Presenters

Ilan Samish, PhD, Founder & CEO, Amai Proteins |Amai Proteins, Healthy Sweetener by Precision Fermentation – Backed by Clinical Study

Ravit Darshan, PhD, CTO, Novid 20, Evidence Based Antiviral Nutritional Supplement Derived from Cinnamon

Eli Faraggi, Co-Founder & CEO, InnoBev | Clinically Proven IP Protected  Ingredients that Improve Focus by Chronobiology

Stav Peled, PhD Student, Technion – Israel Institute of Technology | Next-generation prebiotics: selective targeting of proteins to probiotic

Leehen Mashiah, PhD Student, Technion- Israel Institute of Technology | Sex-Based Variations in the In Vitro Digestibility of  Liquid and Powdered Milk and Oat Alternatives: Implications for Nutritional Bioaccessibility

Guy Michrowski, Founder & CEO, Profuse | Cultivated Muscle: A New Frontier for Drug Discovery

Professional Regulatory Perspective

Brian P. Sylvester, Partner, Morrison Foerster, FDA & Healthcare Regulatory and Compliance Group